Search
Search Results
-
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
Pantoprazole is used to treat gastroesophageal reflux disease (GERD), maintain healing of erosive esophagitis (EE), and control symptoms related to...
-
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
Irbesartan, a potent and selective angiotensin II type-1 (AT 1 ) receptor blocker (ARB), is one of the representative medications for the treatment of...
-
Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism
Pitavastatin, a potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is indicated for the treatment of hypercholesterolemia and mixed...
-
Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes
The aim of this study was to establish the physiologically based pharmacokinetic (PBPK) model of flurbiprofen related to CYP2C9 genetic polymorphism...
-
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder, social anxiety...
-
Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism
Piroxicam is a non-steroidal anti-inflammatory drug used to alleviate symptoms of osteoarthritis and rheumatoid arthritis. CYP2C9 genetic...
-
Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes
Meloxicam, a non-steroidal anti-inflammatory drug, is used for the treatment of rheumatoid arthritis and osteoarthritis. Cytochrome P450 (CYP) 2C9...
-
-
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and a representative selective cyclooxygenase (COX)-2 inhibitor, which is commonly...
-
Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes
Metoprolol, a selective β 1 -adrenoreceptor blocking agent used in the treatment of hypertension, angina, and heart failure, is primarily metabolized...
-
Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients
Candesartan cilexetil is an angiotensin II receptor blocker and it is widely used to treat hypertension and heart failure. This drug is a prodrug...
-
Pharmacometrics: The Already-Present Future of Precision Pharmacology
The use of mathematical modeling to represent, analyze, make predictions or providing information on data obtained in drug research and development...
-
Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines
Nanoparticles (NPs) have distinct pharmacokinetic (PK) properties and can potentially improve the absorption, distribution, metabolism, and...
-
Improving Development of Drug Treatments for Pregnant Women and the Fetus
The exclusion of pregnant populations, women of reproductive age, and the fetus from clinical trials of therapeutics is a major global public health...
-
Simulation for Pharmaceutics and Pharmaceutical Industry
Simulation is an essential tool in the pharmaceutical industry, providing researchers with valuable insights and predictions to aid drug development,...
-
Simulation for Pharmaceutical Chemistry
Simulation is a powerful tool in pharmaceutical chemistry that allows researchers to predict the behavior of molecules and drug compounds. It is an...
-
Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
Tolperisone, a muscle relaxant used for post-stroke spasticity, has been reported to have a very wide interindividual pharmacokinetic variability. It...
-
Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects
Glipizide is a second-generation sulfonylurea antidiabetic drug. It is principally metabolized to inactive metabolites by genetically polymorphic...
-
Pharmacometrics in Pediatrics
Pharmacometrics have advanced from compartmental analysis to noncompartmental analysis and population pharmacokinetics that require complicated...
-
Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
The occurrence of drug–drug interactions (DDIs) can significantly affect the safety of a patient, and thus assessing DDI risk is important. Recently,...
